Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus placebo added to DMARDs in moderate to severe active rheumatoid arthritis
2004-005210-37Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tocilizumab + traditional DMARD therapy with Placebo + traditional DMARD therapy (2 arms). Primary endpoint: ACR20 response at week 24. Started Mar 2005; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-005210-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005210-37.